Articles tagged with Metabolic Disorders
The Pennington-Louisiana Nutrition Obesity Research Center has received a five-year, $5.66 million renewal grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The award reaffirms Pennington Biomedical's position as a national leader in nutrition, obesity, and metabolic health research. The center su...
Dr. Kaja Falkenhain receives the Peter J. Reeds Early Career Investigator Award for her groundbreaking work on human nutrition and metabolism. Her research focuses on cardiometabolic health and glycemic control, highlighting the impact of nutritional exposures on energy expenditure.
Researchers propose using the glucose ketone index (GKI) to track metabolic health in non-communicable diseases, which cause three in four deaths worldwide. The GKI measures blood glucose and ketones and may indicate metabolic state, assess long-term nutritional adherence, and support mitochondrial function improvement.
A new review calls on Mexico to add liver health to its existing chronic disease programs, citing the country's high liver disease prevalence. Liver disease affects nearly half of Mexican adults and is linked to diabetes and obesity.
A new study published in Hepatobiliary Communications reveals that standard CT scans can detect stage-specific tissue patterns predicting severe liver complications in chronic hepatitis B-related cirrhosis. Visceral fat and muscle shifts carry different warning meanings based on the patient's disease stage.
A new study from Pennington Biomedical Research Center in Louisiana demonstrates safe and effective bariatric surgery outcomes for young patients with severe obesity. The study found significant improvements in weight loss and obesity-related health conditions, highlighting the importance of multidisciplinary care models.
Researchers developed a new mouse model that closely reproduces eosinophilic gastritis, identifying key immune pathways and mechanisms behind the disease. The study provides a biological explanation for therapies targeting IL-4Rα, suggesting potential improvements in treatment precision.
Researchers found that yeast-based supplements can reprogram early-stage immune cells to produce enhanced anti-tumor responses. The study suggests a potential solution for obesity-related immune dysfunction and cancer, using a food-grade supplement with an excellent safety record.
Dr. Joe Northup, a renowned metabolic and bariatric surgeon, has been elected the 40th president of ASMBS. He aims to ensure patients understand the role of surgery in comprehensive obesity care.
The study demonstrated sustained improvements in disease features in mouse models with effects lasting throughout their lifespan. Genespire's approach has the potential to translate into human health as a single-administration treatment for patients with MMA.
A large Swedish study found that certain bacteria in the gut microbiota can be seen in people who develop type 2 diabetes years later. Fluctuations in metabolism and low fibre intake may also contribute to the risk. The discovery paves the way for early identification of at-risk individuals.
The NUTRITION 2026 meeting will present over 1,650 scientific presentations on topics including food additives, GLP-1 therapies, and ultra-processed foods. Experts will discuss the latest research on potential risks and clinical considerations of these substances.
The study found a 37% increase in obesity and a two-fold increase in severe obesity among both adults and youth over 20 years. Obesity rates have major implications for cardiovascular disease and mortality, highlighting the need for targeted initiatives to address the rising epidemic.
Researchers have identified high rates of overweight/obesity (82%) and hypertension (higher than statewide average) in Franklin Parish, with income levels linked to lower hypertension rates. Older residents are also more likely to have undiagnosed high cholesterol and diabetes.
A CU Anschutz study reveals reduced mitochondrial efficiency in healthy yet sedentary individuals, which may precede the development of major diseases like cancer, diabetes, and Alzheimer's. Regular exercise acts as a literal shield for cellular health, helping mitochondria seamlessly switch between burning fat and carbohydrates.
A study found that nearly 4 in 10 patients stopped GLP-1 medication within the first year and nearly two-thirds restarted therapy within two years. The researchers also identified sociodemographic, clinical, and provider-level predictors of discontinuation, including Medicaid or Medicare status, Black patients, and side effects.
A study found that adults taking GLP-1 receptor agonist medications experienced significant decreases in daily step counts and moderate-to-vigorous physical activity, highlighting the need for targeted interventions to promote exercise alongside obesity treatment.
The study found a significant increase in type 1 diabetes cases among Hispanic/Latino adolescents in Puerto Rico, from 10.1 per 100,000 in 2009 to 24.1 in 2021, with an average annual increase of 4.1%. This trend has important implications for patient care and public health.
A recent study of 42,000 adults taking blood pressure medications and GLP-1s found higher rates of hypotension events, including dizziness and fainting. The study highlights a potential safety concern for patients aged 65 and older and those with diabetes.
A new study by Tampere University researchers found that maternal pre-pregnancy hypertension and child body composition may contribute to the development of fatty liver disease. The study also identified dietary factors, such as high protein intake and low fruit consumption, as risk factors for elevated liver enzyme levels in children.
A new study by Pennington Biomedical and collaborators found that Americans with the highest levels of obesity are undergoing fewer surgical procedures overall. Despite the increasing prevalence of extreme obesity, these individuals appear to be receiving proportionally fewer surgical interventions each year. The research highlights gr...
Researchers at UVA are testing the SIPsmarter program to reduce sugary drink consumption among children and their parents. The study aims to improve beverage quality and overall health outcomes in rural areas with high rates of sugary drink consumption.
Adults with both obesity and an autoimmune disease who took a GLP-1-based medication had fewer emergency department visits and lower mortality rates compared to those not taking the medication. The study analyzed data from over 26,000 adults treated in the OneFlorida+ network between 2014 and 2024.
A new study published in JAMA Network Open found that removing olfactory groove meningioma may improve blood sugar control and weight in some patients with diabetes. The research team tracked long-term changes in hemoglobin A1c levels after tumor removal surgery.
Researchers from Pennington Biomedical will showcase their latest findings on prevention, care, and cures for diabetes and obesity at the American Diabetes Association's 2026 Scientific Sessions. The sessions will highlight cutting-edge advancements driving progress in diabetes research and management.
Researchers at Pennington Biomedical published the first study to estimate pediatric obesity prevalence among US children and adolescents aged 5-18 years using the new Lancet Commission definitions. The study found that many children are already experiencing measurable health impairments associated with obesity.
Researchers highlight latest developments in pathology, diagnosis, and treatment of MASLD and IPFD, revealing correlations with chronic diseases like liver cancer and pancreatic cancer. Innovative treatments, such as AI-driven approaches and organ-targeted therapies, show promise for precision prevention and therapy.
A new study published in JAMA Neurology finds ecopipam to be effective in suppressing tics in patients with Tourette syndrome. The medication was well-tolerated and showed no significant adverse effects over a period of up to 24 weeks.
A major new study has found that severe asthma patients are often battling other health conditions, with nearly all suffering from at least one major issue. The study identified three distinct profiles linked to how well asthma is controlled and the treatments needed, offering potential breakthroughs for improving care.
A research study, COACH trial, is testing different ways to help children and families improve their health through lifestyle changes delivered by primary care clinics. The study aims to assess the effectiveness of personalized nutrition counseling, community resources, and online interactive lessons on weight management.
A study published in Nature Metabolism has found a crucial link between mitochondrial lipid deficiency and gut inflammation, revealing that cardiolipin plays a key role in maintaining immune homeostasis. The research suggests that targeting the metabolism of immune cells could be a new approach to treating inflammatory bowel diseases.
Researchers are developing a multi-organ model on a chip to study the complex interactions between organs, hormones, and cells in diabetes and dementia. The GlucoBrain project aims to understand how signals move between the brain, gut, and pancreas, potentially leading to new treatments for millions affected by these diseases.
Researchers found that gut luminal exosomes from older animals carried molecular signals associated with insulin resistance, inflammation and disruption of the gut barrier. Transferring these to young animals elicited similar effects, while transferring exosomes from young animals to older animals mitigated metabolic aging findings.
Research found that girls born to mothers with higher insulin resistance during pregnancy are more likely to have more abdominal fat at age 7. Maternal insulin resistance was not associated with body fat in boys, suggesting girls may be more susceptible to the mother's insulin resistance during late pregnancy.
Professor Eiichi Araki's pioneering research on insulin signaling has led to a deeper understanding of the molecular mechanisms of diabetes. His discoveries remain foundational for researchers striving to overcome insulin resistance and improve treatment options.
A cohort study found a potential association between GLP-1 RA use and improved survival rates among obese breast cancer patients with related metabolic conditions. Further evaluation of GLP-1 RA therapy in randomized clinical trials is warranted based on these findings.
The summit brought together endocrine leaders to identify opportunities to work closely together on increasing the visibility of endocrine health in policy decisions. Early findings from a workforce survey revealed challenges including long patient waiting times and retention concerns among early-career clinicians.
A study published in Cancer Medicine reveals that the same genes active in pancreatic cancer are also linked to obesity and diabetes, driving inflammatory and immune pathways. This discovery helps explain poorer cancer outcomes for those with metabolic disease and offers new avenues for targeted treatment.
A $10 million grant from the National Institute of Environmental Health Sciences will support research on PFAS health effects and translate discoveries into real-world solutions. The study aims to identify links between PFAS exposure and metabolic conditions, such as obesity and type 2 diabetes.
A large real-world study comparing bariatric surgery to GLP-1 drugs found that surgery produced significantly greater weight loss and higher rates of obesity-related disease remission. After 12 months, patients who underwent surgery achieved more than 20% greater weight loss than those treated with GLP-1 therapy.
Researchers identified a unique metabolic fingerprint in the hearts of patients with heart failure with preserved ejection fraction (HFpEF) and obesity. The study reveals disrupted glucose metabolism and accumulated metabolic products, which are linked to structural changes in the heart and disease severity.
A review from Florida Atlantic University links obesity to Alzheimer's disease through disruptions in metabolism, highlighting the importance of mitochondrial function and gut-brain axis balance. Early detection and whole-body prevention may become possible through monitoring metabolic health.
A new study from Rice University finds that using GLP-1 medications can lead to social judgment, even among those who have lost significant weight. Participants rated individuals who used GLP-1 more negatively than those who lost weight through diet and exercise or did not lose weight at all.
A new approach for treating obesity and type 2 diabetes has been developed using a hybrid molecule that targets specific cells. The treatment combines the well-known GLP-1/GIP signalling pathway with an additional metabolic modulator, delivering improved blood-glucose values and weight loss.
Research reveals reduced portal insulin in HCV patients, correlating with proinflammatory cytokines and altered immune responses. This finding indicates a potential link between the immune system and insulin dynamics in HCV infection, with implications for managing dysglycemia.
Researchers reveal how expansion of bone marrow fat promotes immunosuppressive PD-L1 signaling, leading to enhanced osteoclast activity and accelerated bone loss. Reducing bone marrow fat improves bone structure.
The European Society of Endocrinology organizes World Hormone Day to educate the public about hormone-related health issues. Global endocrine disorders affect millions worldwide, emphasizing the need for proper hormone balance.
A study published in PLOS Medicine has identified two new genetic pathways contributing to cardiometabolic disease, including heart disease and obesity. The research analyzed lipid metabolites and their link to disease, suggesting that targeting specific metabolic pathways could prevent or lower the risk of disease.
A new international survey reveals that adults with hypophosphataemic osteomalacia face a substantial disease burden, often under-recognised. The study calls for improved awareness, education, and coordinated care to ensure timely diagnosis and optimal treatment.
A Japanese study examines the long-term effects of COVID-19 lockdowns on individuals with glucose intolerance, revealing a clear divergence in clinical trajectories among those who worsened and improved. Flexible lifestyle adaptation is crucial for restoring metabolic health, suggesting personalized support may improve glycemic control.
A Salk Institute study identifies Fibroblast Growth Factor 1 (FGF1) as the molecular signal that tells the liver when to release fat into the bloodstream, following a precise rhythm timed to the body's internal clock.
A study identified exosomal microRNA-122-3p as a key driver of MASLD pathogenesis. Elevated miR-122-3p levels induced triglyceride accumulation and reactive oxygen species production in liver cells.
A new report published in Nature Metabolism sheds light on fructose's distinct role in driving metabolic disease, separate from its caloric contribution. Fructose bypasses key regulatory steps, leading to increased fat synthesis and cellular energy depletion, which may contribute to metabolic syndrome.
Professor Noriko Yoshimura has received the IOF CSA Medal of Achievement for her pioneering work on epidemiology and prevention of locomotive organ disorders and osteoporosis. Her research, including the ROAD Study, has significantly advanced understanding of musculoskeletal health.
Professor Thierry Chevalley has received the prestigious IOF President's Award for his significant contributions to advancing bone health and osteoporosis prevention. With extensive research expertise in geriatrics and bone health, he serves on various scientific committees and leads efforts to develop fracture liaison services.